Afrezza Scripts

Investor here, can one of the reps explain why Afrezza scripts are so low? From all indications, patients do extremely well on Afrezza yet it is not prescribed heavily. I would love to understand the challenges that the reps and company have selling the product.

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Friday scripts are going to include Brazil.

Not

post

at the Wainwright Conference will Mike finally announce a clear & transparent new strategy & approach to grow scripts in the United States that are currently showing flat growth since peak 2018 weekly results were achieved on 12/21/2018. On 12/19/18 Mike issued a press release announcing a $40 million stock offering intended to fund a 2019 strategic plan to grow Afrezza sales, that included an expensive $9 million television ad campaign.

Based on recent 8/23/19 weekly script results, its clear 2019 strategic plan funded with a $40 million stock offering isn't working & has lead to more shareholder value destruction. Mike can twists & turn information to try an make his strategies and results look good, but the numbers themselves don't lie. Afrezza sales have plateaued and are no longer growing. Here is week to week comparison 12/21/18 NRx = 381 RRx = 376 TRx = 757 Sales = $1.1 million vs 8/23/19 NRx = 327 RRx = 378 TRx 505 Sales $1.2 million. Need US Partner or Sell Afrezza

Friday scripts are going to include Brazil.

post

at the Wainwright Conference will Mike finally announce a clear & transparent new strategy & approach to grow scripts in the United States that are currently showing flat growth since peak 2018 weekly results were achieved on 12/21/2018. On 12/19/18 Mike issued a press release announcing a $40 million stock offering intended to fund a 2019 strategic plan to grow Afrezza sales, that included an expensive $9 million television ad campaign.

Based on recent 8/23/19 weekly script results, its clear 2019 strategic plan funded with a $40 million stock offering isn't working & has lead to more shareholder value destruction. Mike can twists & turn information to try an make his strategies and results look good, but the numbers themselves don't lie. Afrezza sales have plateaued and are no longer growing. Here is week to week comparison 12/21/18 NRx = 381 RRx = 376 TRx = 757 Sales = $1.1 million vs 8/23/19 NRx = 327 RRx = 378 TRx 505 Sales $1.2 million. Need US Partner or Sell Afrezza

post

Nice pop above 600 this week with record revenue of $906k. Would love an Afrezza rep sharing if they see this growth continuing.

The growth has been hard for MannKind as Q4 scripts were higher than Q1 of 2019 with 8,290 Afrezza scripts sold in Q4 and 7,741 in Q1, which is a 6.6% decline. This decline is also higher than the 1.4% decline we saw last year in Q1. For such a great concept/product, sales and script growth have been a tough go.

post

Patients love $MNKD Afrezza but it's not being prescribed -

Q3 2018 Script Data

Afrezza scripts dip back below 600.

Afrezza scripts for the quarter were 7,254.

Quarter-over-quarter growth was under 12%.

Nice pop above 600 this week with record revenue of $906k. Would love an Afrezza rep sharing if they see this growth continuing.

post

Patients love $MNKD Afrezza but it's not being prescribed -

Q3 2018 Script Data

Afrezza scripts dip back below 600.

Afrezza scripts for the quarter were 7,254.

Quarter-over-quarter growth was under 12%.

post

Loading...


Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.